Accord Logo

Intended for UK patients and members of the public

Discontinued Other versions of this medicine may still be available. Information for reference purposes.

Ramipril Tablets

Active Ingredients

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at yellowcard.mhra.gov.uk. By reporting side effects, you can help provide more information on the safety of this medicine.

Report a side effect or a product complaint

Discontinued Other versions of this medicine may still be available. Information for reference purposes.

Ramipril 10mg Tablets

PL Number:
0142/0632
MA Holder:
Accord-UK Ltd
Product Classification:
POM
Product Status:
Discontinued

Product Documentation

  • Single Variation

    Variation Type: IB C.I.2.a

     

    Variation Description:

    To register an update to sections 4.3, 4.4, 4.5, 4.6, 4.8 and 5.1 of the SPC in line with the reference product (Tritace 5mg Tablets; PL 04425/0358). Consequentially, the leaflet has been updated.

    Addition of ‘sodium-free’ statement in SPC section 4.4 and PIL.

    Update to product descriptions in PIL section 6.

     

    SmPC sections updated – 4.3, 4.4, 4.5, 4.6, 4.8, 5.1 and 10

    PIL sections updated – Heading, 2, 3, 4, 5 and 6

  • - To remove a batch release site from the leaflet.

    - To correct grammar error found in section 2 of the leaflet.

    - To amend to bring the reporting of side effects statement in line with latest QRD Appendix V (29 February 2024) wording in section 4.

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at yellowcard.mhra.gov.uk. By reporting side effects, you can help provide more information on the safety of this medicine.

Report a side effect or a product complaint

Discontinued Other versions of this medicine may still be available. Information for reference purposes.

Ramipril 2.5mg Tablets

PL Number:
0142/0630
MA Holder:
Accord-UK Ltd
Product Classification:
POM
Product Status:
Discontinued

Product Documentation

  • Single Variation

    Variation Type: IB C.I.2.a

     

    Variation Description:

    To register an update to sections 4.3, 4.4, 4.5, 4.6, 4.8 and 5.1 of the SPC in line with the reference product (Tritace 5mg Tablets; PL 04425/0358). Consequentially, the leaflet has been updated.

    Addition of ‘sodium-free’ statement in SPC section 4.4 and PIL.

    Update to product descriptions in PIL section 6.

     

    SmPC sections updated – 4.3, 4.4, 4.5, 4.6, 4.8, 5.1 and 10

    PIL sections updated – Heading, 2, 3, 4, 5 and 6

  • - To remove a batch release site from the leaflet.

    - To correct grammar error found in section 2 of the leaflet.

    - To amend to bring the reporting of side effects statement in line with latest QRD Appendix V (29 February 2024) wording in section 4.

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at yellowcard.mhra.gov.uk. By reporting side effects, you can help provide more information on the safety of this medicine.

Report a side effect or a product complaint

Discontinued Other versions of this medicine may still be available. Information for reference purposes.

Ramipril 5mg Tablets

PL Number:
0142/0631
MA Holder:
Accord-UK Ltd
Product Classification:
POM
Product Status:
Discontinued

Product Documentation

  • Single Variation

    Variation Type: IB C.I.2.a

     

    Variation Description:

    To register an update to sections 4.3, 4.4, 4.5, 4.6, 4.8 and 5.1 of the SPC in line with the reference product (Tritace 5mg Tablets; PL 04425/0358). Consequentially, the leaflet has been updated.

    Addition of ‘sodium-free’ statement in SPC section 4.4 and PIL.

    Update to product descriptions in PIL section 6.

     

    SmPC sections updated – 4.3, 4.4, 4.5, 4.6, 4.8, 5.1 and 10

    PIL sections updated – Heading, 2, 3, 4, 5 and 6

  • - To remove a batch release site from the leaflet.

    - To correct grammar error found in section 2 of the leaflet.

    - To amend to bring the reporting of side effects statement in line with latest QRD Appendix V (29 February 2024) wording in section 4.

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at yellowcard.mhra.gov.uk. By reporting side effects, you can help provide more information on the safety of this medicine.

Report a side effect or a product complaint

General FAQs

For any further assistance, please get in touch.

View product information as a: